C12N 15/1135
Against oncogenes or tumor suppressor genes
Official title: {against oncogenes or tumor suppressor genes}
C12N15/1135 (Against oncogenes or tumor suppressor genes) appears on 1,073 US grants and 1,870 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,073
- Published applications
- 1,870
- Assignees
- 724
- Inventors
- 2,925
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 8 | 0 |
| 1997 | 27 | 0 |
| 1998 | 23 | 0 |
| 1999 | 27 | 0 |
| 2000 | 35 | 0 |
| 2001 | 23 | 3 |
| 2002 | 22 | 27 |
| 2003 | 13 | 63 |
| 2004 | 15 | 38 |
| 2005 | 8 | 49 |
| 2006 | 12 | 36 |
| 2007 | 9 | 81 |
| 2008 | 8 | 100 |
| 2009 | 46 | 80 |
| 2010 | 55 | 106 |
| 2011 | 44 | 86 |
| 2012 | 43 | 77 |
| 2013 | 45 | 74 |
| 2014 | 58 | 95 |
| 2015 | 57 | 99 |
| 2016 | 61 | 105 |
| 2017 | 60 | 92 |
| 2018 | 61 | 78 |
| 2019 | 53 | 83 |
| 2020 | 52 | 74 |
| 2021 | 42 | 73 |
| 2022 | 41 | 95 |
| 2023 | 29 | 73 |
| 2024 | 36 | 73 |
| 2025 | 25 | 68 |
| 2026 | 25 | 42 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- FATS as a target for treating tumors and uses thereof6 Oct 2026US 12,753,410 B2Tianjin Medical University
- FUS/TLS-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases15 Sep 2026US 12,735,745 B2The General Hospital Corporation
- Pharmaceutical composition containing HERES expression inhibitor for preventing or treating squamous cell carcinoma25 Aug 2026US 12,716,066 B2Industry-Academic Cooperation Foundation, Yonsei University
- Targeting gene amplification in cancer using triplex formation as a therapeutic strategy18 Aug 2026US 12,709,645 B2Yale University
- Edible plant exosome-like nanovectors for vaccination11 Aug 2026US 12,702,703 B2University of Louisville Research Foundation, Inc.
- Methods for mitigating cardiac aging and stress and improviing cardiac function8 Oct 2026US 2026/0308593 A1San Diego State University (Sdsu) Foundation, Dba San Diego State University Research Foundation
- Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof17 Sep 2026US 2026/0273070 A1City of Hope
- Compositions and methods useful for the treatment and management of obesity associated metabolic dysfunction10 Sep 2026US 2026/0265752 A1The Children’s Hospital of Philadelphia
- Conjugate compositions comprising phosphoryl guanidine linkages and uses thereof27 Aug 2026US 2026/0250683 A1Avidity Biosciences, Inc.
- Methods of treating pancreatic cancer27 Aug 2026US 2026/0250684 A1The Regents of the University of California
Most cited
By later US patents
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Inhibition of cell proliferation using antisense oligonucleotides753US 5,756,476 AThe United States of America as represented by the Department of Health and Human Services · 1998
- Oligonucleotides having phosphorothioate linkages of high chiral purity626US 5,587,361 AIsis Pharmaceuticals, Inc. · 1996
- Oligonucleotides containing N-2 substituted purines621US 5,587,469 AIsis Pharmaceuticals, Inc. · 1996
- Oligoribonucleotides and ribonucleases for cleaving RNA486US 6,107,094 AIsis Pharmaceuticals, Inc. · 2000